conducted target trial emulations comparing dual GLP-1/GIP agonists to GLP-1 monotherapy in patients with type 2 diabetes, finding that dual agonists were linked to numerically lower risks of MALOs, although confidence intervals overlapped, suggesting that extended observation period and larger patient cohorts may be needed to definitively establish comparative effectiveness [61]
Other Emerging Innovators The T2D R&D pipeline includes molecules from companies like Regor Pharmaceuticals, Eccogene, Sciwind Biosciences, MediciNova, Sparrow Pharmaceuticals, HighTide, Biopharma Pty Ltd, and Biomea Fusion Inc
They may not explain whether evidence comes from animals, cells, small early studies, or human clinical trials
Zeng, Y
You can also explore how our peptide treatment program at Perfect B supports body composition and skin quality during and after weight loss
We are committed to providing innovative and effective solutions for patients seeking to improve their metabolic health and achieve sustainable weight loss
